Objective: to determine contributors to decline in functional capacity in elderly patients with known vascular risk factors or disease. Design: secondary analysis of longitudinal data gathered over an average 3.2 years of follow-up. Participants: 5,804 community-dwelling subjects aged 70-82 years with a history of, or risk factors for, ischaemic vascular disease. Measurements: basic activities of daily living were measured serially through the study using the 20-point Barthel index and extended activities using a 14-point Instrumental Activities of Daily Living (IADL). Results: over the period of study 896/5,661 (16%) subjects had deterioration in Barthel (mean reduction 0.35, SD 1.76) and 1,270/5,662 (22%) had a reduction in IADL score (mean 0.63, SD 2.15). Independent risk factors at baseline for a reduction in Barthel and IADL were age, female gender and diabetes mellitus. A history of vascular disease and smoking were also significant predictors of reduction in IADL. The development of a new cerebrovascular event was associated with a greatly increased risk of reduction in the Barthel and IADL score (multivariate OR 3.71 (95% CI 2.94, 4.69) and 3.71 (95% CI 2.96, 4.66), respectively). A similar pattern was seen for non-fatal myocardial infarction. Incident cerebrovascular events and nonfatal myocardial infarction accounted for 31 and 11%, respectively, of the population decline in Barthel, and 24 and 10% of the decline in IADL. Conclusion: incident vascular events were important contributors to functional decline in this population, accounting for almost half of the observed deterioration in basic activities of daily living and approximately one-third of the reduction in IADL. Prevention of ischaemic vascular events over the short to medium term should reduce the burden of disability in high-risk older subjects.
Introduction
Decline in functional capacity and disability are common problems in old age. Disability can be defined as restriction, resulting from diseases and impairments, in the ability to perform normal activities of daily living (ADL) [1] . It is estimated that severe disability is present in 13% of the over80s in the UK. Milder degrees of disability are even more common. Healthy lifestyle, including non-smoking, nonobesity and regular exercise, is associated with both increased life expectancy and a reduced period of disability before death [2, 3] . A possible mechanism for this reduction in period of end-of-life disability is prevention of vascular disease. This is supported by longitudinal studies which show that cardiovascular diseases, including coronary heart disease, are associated with disability in the elderly [4] [5] [6] [7] [8] [9] [10] . However, not all studies support association between decline in functional abilities and cardiovascular risk factors [11, 12] .
Therefore it is not certain whether prevention of vascular disease in older people will significantly reduce the population burden of disability.
In this study we aimed to determine contributors to decline in functional capacity in elderly patients with known vascular risk factors or disease, using the cohort of patients followed up longitudinally in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) [13] .
Methods
We performed a secondary analysis of data gathered from 5,804 subjects recruited to PROSPER [13] . This was a multicentre, randomised, double-blind, placebo-controlled trial of pravastatin in the prevention of vascular disease in the elderly. Men and women aged 70-82 years with evidence of preexisting vascular disease or at least one major risk factor for vascular disease (hypertension, diabetes mellitus or smoking) were randomised to pravastatin (40 mg per day) or placebo. Vascular disease at study entry was defined as physiciandiagnosed stable angina or intermittent claudication, ischaemic stroke, transient ischaemic attack (TIA), myocardial infarction (MI), arterial surgery or amputation for vascular disease. A total of 23,770 individuals in the primary care setting were invited to attend an initial screening visit conducted by a study nurse, at which consent for the screening process, a brief medical history and vital signs were recorded, and dietary and appropriate health advice given. In Scotland (n= 11,770) and Ireland (n= 10,157), the subjects were invited in an unselected manner. In the Netherlands (n= 1,843), however, subjects were pre-selected on the basis of possession of previously known cardiovascular risk factors. From this screening process 5,804 subjects were included in the study. Of these subjects 3,000 (51.7%) were women and 3,239 (55.8%) had vascular risk factors but no known vascular disease; 914 (32.6%) of the men and 644 (21.5%) of the women were current smokers at study entry (Table 1) . Study visits were conducted approximately every 3 months. Follow-up averaged 3.2 years and included recording of all vascular events and cancers. The primary end point of the trial was the combined end point of coronary heart disease death, non-fatal MI, fatal plus non-fatal stroke, plus other vascular deaths. Stroke was defined as: (i) rapid onset of focal neurological deficit lasting ≥24 hours, (ii) focal neurological deficit mode of onset uncertain but with no plausible evidence of alternative (non-stroke) cause, or (iii) rapid onset of global neurological deficit (e.g. coma) lasting ≥24 hours with no other plausible non-stroke cause. Transient ischaemic attacks were defined as rapid onset of focal neurological deficit lasting <24 hours. Myocardial infarction was defined as: (i) ischaemic cardiac pain greater than 30 minutes duration (and/or unexplained acute left ventricular failure) and diagnostic cardiac enzymes, (ii) ischaemic cardiac pain and/or unexplained acute left ventricular failure with both equivocal enzymes and equivocal electrocardiogram, (iii) diagnostic enzymes and equivocal electrocardiogram, (iv) angiographic evidence of occlusion of a major artery with appropriate ventriculographic wall motion abnormality where previous angiogram since randomisation showed no such abnormality, or (v) an electrocardiogram at an annual or at an unscheduled visit showing a MI that was not evident on the previous electrocardiogram. The detailed protocol of PROS-PER including study design, definitions of outcomes, baseline characteristics and the results of the intervention study are published elsewhere [13] [14] [15] .
To assess change of functional status, the 20 point Barthel and Instrumental Activities of Daily Living (IADL) questionnaires, using a modified version of the OARS questionnaire, were completed at the baseline visit and repeated during the study at 9, 18 and 30 months and at the last visit (if later than 30 months). The Barthel index is a measure of basic ADL and the IADL measures extended ADL [16] [17] . There were no important differences in any of these measures between the subjects recruited on the basis of primary or secondary prevention [14] .
Statistical analysis
We calculated changes in functional capacity (Barthel and IADL) between baseline and 9, 18 and 30 months, as well as between baseline and each subject's last recorded measurement (this ranged between 9 and 45 months). Due to skewness of data, patients were then dichotomised into those with a reduction in functional capacity (1 point or more) versus those with no change or an increase in functional capacity at each visit. For subjects without data at 18 and 30 months (and still alive) the score from the previous visit was carried forward. Separate analyses were performed for the Barthel index and IADL for each follow-up visit and subjects' last recorded measurement. The reduction in functional capacity was analysed using multivariate logistic regression models.
Covariates included age, gender, history of diabetes, history of hypertension, history of any vascular disease, smoking status, treatment allocation, baseline value for Barthel or IADL (where appropriate), incidence of MI and incidence of stroke/TIA during study, and length of follow-up. Baseline and follow-up variates were fitted separately and then included together in one model. Actual change in functional capacity was compared between cases (incidence MI, stroke/TIA or cancer) and noncases using the Wilcoxon rank sum test. Individual group changes were tested using the Wilcoxon sign ranked test.
Baseline statistics are reported as mean (SD) for continuous variables and number (%) for categorical variables unless otherwise stated.
Results
Over the period of study 896/5,661 (16%) subjects with follow-up measurements had deterioration in Barthel (mean reduction 0.35, SD 1.76) and 1,270/5,662 (22%) reductions in IADL score (mean 0.63, SD 2.15). The factors associated with a decrease in Barthel score at subjects' last visit compared with baseline are shown in Table 2 . The independence of these factors as predictors of a decrease in Barthel at 9, 18 and 30 months from baseline were also assessed (discussed in the text). The odds ratios (ORs) (and significance) for baseline variates (model 1) and follow-up variates (model 2) changed little after adjustment for each other (model 3).
From the multivariate models the independent baseline risk factors for a reduction in basic ADL were age and female gender. Of the cardiovascular risk factors only diabetes mellitus was independently associated with increased risk of disability. A history of hypertension, smoking or vascular disease did not significantly increase the risk of decline in basic or instrumental ADL.
The development of stroke or TIA during follow-up increased the risk of decline in ADL (OR 3.71 (95% CI 2.94, 4.69), P < 0.0001). Similar results were seen for 9, 18 and 30 months. A non-fatal MI increased the risk of functional decline at the end of the observational period (1.38 (1.07, 1.78), P = 0.014), although not at visits throughout study (1.09 (0.54, 2.20), P = 0.81 at 9 months; 1.29 (0.79, 2.09), P = 0.31 at 18 months; 1.35 (0.96, 1.90), P = 0.081 at 30 months).
The associations of a reduction in IADL score at subjects' final visit from baseline are shown in Table 3 . As for the Barthel scores the association with baseline risk factors (model 1) and follow-up variates (model 2) remained consistent after adjustment for each other (model 3). The independent baseline risk factors for decline in extended ADL were age and female gender. Of the cardiovascular risk factors, diabetes mellitus, history of any vascular disease and smoking were significantly associated. The development of a new stroke was associated with a greatly increased risk of reduction in the IADL score (OR 3.71 (95% CI 2.96, 4.66, P < 0.0001)) at We also investigated whether a non-linear relationship between blood pressure and disability might exist (such as a J-shaped curve) and performed analysis of blood pressure in quintiles. No consistent linear or non-linear relationship between blood pressure (systolic blood pressure, diastolic blood pressure or pulse pressure) and decrease in functional capacity (change in Barthel or IADL scores) could be found (data not shown). The influence of hyperlipidaemia on a change in Barthel or IADL scores was also investigated. No significant relationship was found. However, there was a trend for ADL to decline more in the placebo group than in those treated with pravastatin with a mean between-group difference for Barthel index of 0.06 (95% CI −0.03, 0.16) and for IADL of 0.03 (−0.08, 0.14).
The magnitude of effect on functional status of developing a new stroke or TIA, non-fatal MI or newly diagnosed cancer is presented in Table 4 . Non-fatal MI accounted for 11 and 10% of the decline in basic and instrumental ADL, respectively, compared with 31 and 24% for cerebrovascular events and 6 and 7% for cancers.
Discussion
We found that age, gender and diabetes mellitus are independent risk factors for decline in both basic and extended ADL in an elderly population with vascular disease or risk factors. Incident cerebrovascular events and MI contributed significantly to functional decline; however, calculations of attributable impact indicate that the combination of these ischaemic vascular events account for less than half of the reduction in basic ADL and about one-third of the reduction in instrumental ADL. Cerebrovascular disease on its own accounts for approximately one-third of the reduction in basic ADL and one-quarter that of instrumental ADL. These data give detailed information on the possible functional benefits for older people from prevention of cerebrovascular events and MI over the short to medium term. Our data suggest that in such patients, up to 50% of the decline in function can be prevented by prevention of vascular events. Therefore the potential for effective vascular prevention strategies to prevent disability is substantial. PROSPER found that cholesterol lowering with pravastatin significantly reduced the incidence of ischaemic vascular events but did not significantly affect basic or extended ADL. However, the magnitude of effect of pravastatin on vascular events was not large with a relative risk reduction of 14%, and benefit was largely confined to prevention of MI. Effective prevention of disability is more likely with interventions that prevent stroke.
Our data do have limitations. The group studied was selected and is not representative of the older population as a whole. However, baseline characteristics suggest they are likely to be reasonably representative of older patients who are considered for vascular event prophylaxis. The length of followup at 3.2 years is not long. This should not be a problem in determining the effects of stroke on physical function as the impact occurs immediately, but the disabling effects of MI that are associated with heart failure may not become fully apparent over this time period. However, it could be argued that in Table 3 . Multivariate logistic regression for predictors of decrease in IADL at subjects' last recorded measurement compared with baseline measurement the older population with limited life expectancy we should not want very prolonged periods to obtain clinical gain. It is possible that the observed functional decline is not a direct result of MI or stroke but might be caused by a secondary cause, e.g. a fall resulting in a hip fracture, that happened after the vascular event. However, this does not invalidate our observation that MI or stroke is associated with impaired functional capacity during the follow-up. Our data are consistent with baseline disability predicting future functional decline. One possible mechanism for this association is a greater burden of vascular disease in elderly patients with disability. Mild disability is a risk factor for stroke, where again it may act as a marker of underlying vascular disease. It is possible that we have underestimated the impact of cardiovascular events on disability, as we used questionnaires which are not sensitive to change in performance at higher levels of function (ceiling effects). Our definition of functional decline (any decrease of 1 point or more on the 20-point Barthel or 14-point IADL scale) was pragmatic, enforced by the relatively modest decreases in functional capacity seen over the course of the study. Our definition of disability will have resulted in some (so-called 'non-differential') misclassification, but the effect of this will be to reduce statistical power and does not invalidate the results. Strengths of the study include the large cohort size, with systematic standardised protocol for documentation of events.
Our study is consistent with previous publications which have found that being elderly and being female are risk factors for developing disability [10] . The mechanism for increased risk with female gender is controversial but the reduced skeletal muscle power-weight ratio in women compared with men, and thus reduced physical reserve, is likely to be an important factor. Other investigators have also found that cerebrovascular disease, coronary artery disease and diabetes mellitus are important contributors to disability [6, 18, 19] . In our study hypertension was not a risk factor for the development of disability. Hypertension in the long term is a risk factor for cardiovascular mortality [20] . Our study had a duration of 3.2 years, and we should be cautious about extrapolating these results to longer-term outcomes.
In conclusion we have found age and female gender to be important non-modifiable risk factors for decline in functional capacity in older people with vascular risk factors or disease. Diabetes mellitus is also associated with particular increased risk of functional decline. Incident vascular events are important contributors to functional decline in this population, accounting for almost half of the observed deterioration in basic ADL and approximately one-third of the reduction in IADL. Prevention of ischaemic vascular events over the short to medium term should reduce the burden of disability in high-risk older subjects.
Key points
• Age and female gender are important non-modifiable risk factors for decline in functional capacity in the elderly.
• Diabetes mellitus is associated with a particular increased risk of functional decline in the elderly. Only the first event for each subject is included (unless two events occurred on same day). Events after subjects' last recorded measurement are excluded. • Incident vascular events are important contributors to functional decline in elderly patients with known vascular risk factors or disease.
